Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Accounts Payables: 2020-2024

Historic Accounts Payables for Mirum Pharmaceuticals (MIRM) over the last 5 years, with Dec 2024 value amounting to $14.6 million.

  • Mirum Pharmaceuticals' Accounts Payables rose 27.47% to $12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.2 million, marking a year-over-year increase of 27.47%. This contributed to the annual value of $14.6 million for FY2024, which is 97.11% up from last year.
  • Per Mirum Pharmaceuticals' latest filing, its Accounts Payables stood at $14.6 million for FY2024, which was up 97.11% from $7.4 million recorded in FY2023.
  • Mirum Pharmaceuticals' Accounts Payables' 5-year high stood at $14.6 million during FY2024, with a 5-year trough of $3.2 million in FY2020.
  • In the last 3 years, Mirum Pharmaceuticals' Accounts Payables had a median value of $8.7 million in 2022 and averaged $10.2 million.
  • As far as peak fluctuations go, Mirum Pharmaceuticals' Accounts Payables skyrocketed by 190.89% in 2021, and later declined by 14.66% in 2023.
  • Over the past 5 years, Mirum Pharmaceuticals' Accounts Payables (Yearly) stood at $3.2 million in 2020, then skyrocketed by 190.89% to $9.2 million in 2021, then fell by 5.19% to $8.7 million in 2022, then declined by 14.66% to $7.4 million in 2023, then spiked by 97.11% to $14.6 million in 2024.